Table 1. Baseline Patient Characteristics.

From: Enhancing Home Blood Pressure Management: Implementation of the Sacubitril/Valsartan Treatment in Practical Clinical Settings

n = 55
Sex, male, n (%) 35 (63.6)
Age (years) 68.2 ± 12.3
 <75years, n (%) 35 (63.6)
 ≥75years, n (%) 20 (36.4)
Weight (kg) 69.1 ± 14.0
Body mass index (kg/m2) 25.7 ± 4.5
Morning home SBP (mmHg) 143.6 ± 7.0
Morning home DBP (mmHg) 86.9 ± 12.3
Current smoker, n (%) 3 (5.5)
Other complications, n (%)
 Type 2 diabetes mellitus 5 (9.2)
 Dyslipidemia 33 (60.0)
 Hyperuricemia 18 (32.7)
 Coronary artery disease 6 (10.9)
 Stroke 3 (5.5)
 Sleep apnea syndrome 8 (14.5)
 Chronic kidney disease 10 (18.2)
Antihypertensive drugs, n (%)
 Calcium channel blockers 55 (100)
 Angiotensin receptor blockers 55 (100)
 Angiotensin-converting enzyme inhibitors 0 (0)
 Diuretics 2 (3.6)
 β blockers 5 (9.1)
 Mineralocorticoid receptor antagonists 7 (12.7)
 Others 0 (0)
Table 2. Changes in Health Parameters after Switching from Azilsartan to Sacubitril/Valsartan.

From: Enhancing Home Blood Pressure Management: Implementation of the Sacubitril/Valsartan Treatment in Practical Clinical Settings

Baseline 48 week P-value
Pulse rate (bpm) 74.8 ± 11.0 69.5 ± 9.7 <0.001
eGFRcreat (mL/min/1.73m2) 66.1 ± 14.5 65.4 ± 13.1 0.33
Serum potassium concentration (mEq/L) 4.3 ± 0.3 4.3 ± 0.3 0.39
Serum uric acid concentration (mg/dL) 5.9 ± 1.1 5.5 ± 1.0 <0.001
Plasma BNP concentration (pg/mL) 27.8 ± 21.2 28.9 ± 24.5 0.39
Hemoglobin A1c value (%) 5.8 ± 0.5 5.8 ± 0.5 0.42
PAGE TOP